key: cord-0973348-0ghfjjxh
authors: Galassi, Giuliana; Marchioni, Alessandro
title: Comment on “Predictive factors for a severe course of COVID‐19 infection in myasthenia gravis patients with an overall impact on myasthenic status and survival” by Jakubíková et al.
date: 2021-10-12
journal: Eur J Neurol
DOI: 10.1111/ene.15131
sha: 9a8e3fee05173ca3e4c9358ec0a782f61ce5f358
doc_id: 973348
cord_uid: 0ghfjjxh

We read with interest the report by Jakubíková et al [1] on predictive factors affecting myasthenia gravis (MG) and survival in severe COVID-19 patients in two centers of the Czech Republic. Although the study was certainly conducted with good methodology, our careful reading raised some points of discussion. First, we were impressed by the number of patients enrolled. The authors should provide information regarding the global incidence of COVID-19 in the Czech Republic and the prevalence of MG in the 2 centers of Prague and Brno during the pandemic .

We read with interest the report by Jakubíková et al. [1] on predictive factors affecting myasthenia gravis (MG) and survival in severe COVID-19 patients at two centers in the Czech Republic.

Although the study was certainly conducted with good methodology, our careful reading raised some points of discussion. Third, the authors should specify whether patients were followed and treated in a neurology ward or in an intensive care unit, because MG patients might receive different treatments in the two settings [2] . Interestingly, among the 93 patients with confirmed COVID-19 infection and MG, only 34 were hospitalized. Surprisingly, no patient was in Stage V according to the Myasthenia Gravis Foundation of America classification [2] , that is, in myasthenic crisis (MC), either before, during, or after the infection.

Finally, Jakubíková et al. [1] do not provide radiological details to better define the severity of COVID-19 infection, especially for cases falling into categories scored as 5 and 6. Radiological findings, in our view, are crucial. Different radiological and functional patterns have been described during the course of COVID-19 respiratory failure: patients with lung damage who fulfill acute respiratory distress (ARDS) criteria (type H) and patients with "non-ARDS" (type L) respiratory failure, with lower lung parenchymal involvement [3] . [4] . MG is characterized by fluctuating weakness and fatigability, which may be reversible after rest, involving specific muscle groups, namely, respiratory muscles. This feature could make static respiratory functional measurements less reliable in predicting prognosis than in other neuromuscular diseases (i.e., amyotrophic lateral sclerosis or muscular dystrophies), where the weakness is progressive and not subject to fluctuations.

Finally, the authors [1] stated that long-term use of oral corticosteroids (CS) before COVID-19 increased the risk of severe pneumonia and therefore they suggest avoiding increased dosage during SARS-CoV-2 infection. This assumption is currently unproven and

Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival

Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

Getting rid of weakness in the ICU: an updated approach to the acute management of myasthenia gravis and Guillain-Barré syndrome

dexamethasone in hospitalized patients with Covid-19

Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic status and survival